Akebia Therapeutics Inc

AKBA

1.390USD

+0.010+0.72%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

Akebia Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

55 / 159

Overall Ranking

164 / 4521

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Akebia Therapeutics Inc Highlights

StrengthsRisks

Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with two commercial products for patients impacted by kidney disease. The Company is focused on developing and commercializing therapeutics. Its two preclinical development candidates are AKB-9090 and AKB-10108. The Company’s portfolio and hypoxia-inducible factor (HIF)-based commercialized products include Auryxia (ferric citrate) and Vafseo. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the United States for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA), in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). Vafseo, an oral HIF prolyl hydroxylase (HIF-PH), inhibitor. It utilizes third parties for the commercial distribution of Auryxia, including wholesale distributors and certain specialty pharmacy providers.

Undervalued

The company’s latest PE is -17.77, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 132.23M shares, increasing 1.10% quarter-over-quarter.

Held by PRFDX

Star Investor PRFDX holds 25.11K shares of this stock.

Analyst Rating

Based on 5 analysts

Strong Buy

Current Rating

4.600

Target Price

+233.33%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Akebia Therapeutics Inc is 9.22, ranking 13 out of 159 in the Pharmaceuticals industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 58.77M, representing a year-over-year increase of 57.01%, while its net profit experienced a year-over-year increase of 102.69%.

Score

Industry at a Glance

Previous score

9.22

Change

0



Financials

8.31

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

10.00

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.78

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Akebia Therapeutics Inc is 7.76, ranking 48 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is -17.77, which is -93.85% below the recent high of -1.09 and -33.09% above the recent low of -23.65.

Score

Industry at a Glance

Previous score

7.76

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 55/159

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Akebia Therapeutics Inc is 9.20, ranking 4 out of 159 in the Pharmaceuticals industry. The average price target is 5.00, with a high of 6.00 and a low of 5.00.

Score

Industry at a Glance

Previous score

9.20

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Akebia Therapeutics Inc is 6.58, ranking 118 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 1.52 and the support level at 1.28, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.53

Change

0.05

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Akebia Therapeutics Inc is 3.00, ranking 93 out of 159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 46.40%, representing a quarter-over-quarter increase of 0.03%. The largest institutional shareholder is The Vanguard, holding a total of 15.95M shares, representing 6.01% of shares outstanding, with 24.43% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

16.72M

+0.85%

The Vanguard Group, Inc.

Star Investors

15.48M

+5.94%

State Street Investment Management (US)

11.84M

+48.11%

Geode Capital Management, L.L.C.

6.18M

+1.82%

Alerce Investment Management, L.P.

5.75M

--

Satter Muneer A

5.75M

--

Renaissance Technologies LLC

Star Investors

3.95M

-5.76%

Morgan Stanley & Co. LLC

3.34M

-23.21%

Qube Research & Technologies Ltd

3.21M

+87.00%

Citadel Advisors LLC

3.19M

+37.48%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Akebia Therapeutics Inc is 3.50, ranking 103 out of 159 in the Pharmaceuticals industry. The company's beta value is 0.38. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. Akebia Therapeutics Inc’s latest ESG disclosure leads the Pharmaceuticals industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.

Akebia Therapeutics Inc

AKBA

7.28 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Mckesson Corp

MCK

9.07 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Gilead Sciences Inc

GILD

8.92 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

United Therapeutics Corp

UTHR

8.86 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Regeneron Pharmaceuticals Inc

REGN

8.72 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Mirum Pharmaceuticals Inc

MIRM

8.70 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment